TKIs (EGFR VEGF BTK etc.)

Delve into the world of TKIs (EGFR VEGF BTK etc.) in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on TKIs (EGFR VEGF BTK etc.) to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China
CompanyDeals

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

Shanghai Henlius Biotech, Inc. (HKG: 2696) announced that it has entered into a strategic cooperation with Zhejiang Cancer Hospital, under which the two parties will jointly promote the high‑quality development…

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

Vcare Pharma Partners with CTTQ Subsidiary to Commercialize Eratrectinib – Next‑Generation TRK Inhibitor Approved in China for NTRK Fusion Solid Tumors

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation

CSPC Initiates Phase Ib Trial of JMT206 – First‑in‑Human Dual ActR‑IIA/IIB Monoclonal Antibody Targeting Weight Management with Muscle Preservation

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Ascentage Pharma Announces Clinical Advances for Olverembatinib at ASH

CompanyDrug

BeiGene’s Brukinsa Receives EU Marketing Approval for Marginal Zone Lymphoma

CompanyDrug

HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma

CompanyDrug

BeiGene’s Brukinsa Receives Multiple Marketing Approvals in Latin America

CompanyDrug

Hengrui’s Camrelizumab and Akeso’s AK112 Set to Receive Breakthrough Designation in China

CompanyDrug

BeiGene’s Brukinsa Receives Positive CHMP Opinion for CLL Approval

CompanyDrug

LianBio Cancels Phase III Trial for Truseltiq in China Amid Global Halt

CompanyDrug

BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study

Show More